Pharmacodynamic evaluation of reduced doses of ibrutinib. (A) BTK occupancy in a representative patient with CLL (patient 2) over the course of 3 cycles of treatment with ibrutinib at doses of 420 mg/d (dark blue), 280 mg/d (medium blue), and 140 mg/d (light blue). Mean percentages of BTK occupancy in patients (n = 8) on (B) D1 4 hours, (C) D1 24 hours, (D) D28 24 hours. Error bars represent SEMs. (E) CCL3 levels in patients with CLL over the course of 3 cycles of ibrutinib treatment. (F) Mean decrease in CCL3 levels in patients (n = 9). (G) CCL4 levels over the course of 3 cycles of ibrutinib treatment. (H) Mean decrease in CCL4 levels in patients (n = 9). Error bars represent SEMs. Paired comparisons were performed using 2-sided Wilcoxon signed rank test. ns, not significant.